In an exciting new study, researchers at Brigham and Women’s Hospital in Boston, MA, led by APDA Cotzias Fellowship*...see more
DhivyTM, a carbidopa/levodopa fractionated tablet, is now available
A new formulation of carbidopa/levodopa 25/100, called DhivyTM, is now available. Manufactured by Avion Pharmaceuticals, its innovation is that...see more
New Treatment for Slowness & Stiffness in Parkinson’s Disease
In 2018, Focused Ultrasound was approved to treat tremors in people with PD. Now, the FDA has approved expanding...see more
APDA funding is critical to new research in understanding Levodopa-induced dyskinesias
In an exciting new study, researchers at the Graduate Center, City University of New York (CUNY) and the CUNY...see more
EXCITING GENETIC DISCOVERIES FUNDED BY APDA
May 6, 2021 In an exciting new study, researchers at the APDA Center for Advanced Research at Brigham and...see more
New Clinical Use for Gocovri
Adamas announced that the Food and Drug Administration (FDA) approved Gocovri for a second indication – as an add-on...see more
New technology from Abbott allows for remote programming of DBS device
Abbott, one of the manufacturers of deep brain stimulation (DBS) devices for Parkinson’s disease (PD) recently released NeuroSphereTM Virtual...see more
APDA CENTER AT BRIGHAM AND WOMEN’S HOSPITAL REPORTS EXCITING CORRELATION BETWEEN GLUCOCEREBROSIDASE ACTIVITY AND PARKINSON’S DISEASE
In an exciting new study, researchers at the APDA-funded Center studied the relationship between the activity of the glucocerebrosidase...see more
New Deep Brain Stimulation (DBS) Technology Now Available
Medtronic announces introduction of Percept PC Neurostimulator with Brainsense Technology On June 26, 2020 Medtronic announced the introduction of...see more
A statement from APDA in this time of unrest
All of us at the American Parkinson Disease Association (APDA) support equality for all and reject racism. Our programs...see more